Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M13.0Revenue (TTM) $M0.1Net Margin (%)-9,190.3Altman Z-Score-19.0
Enterprise Value $M4.9EPS (TTM) $-0.5Operating Margin %-12,196.1Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.9Pre-tax Margin (%)-9,190.3Higher ROA y-yY
Price/Book0.810-y EBITDA Growth Rate %-11.2Quick Ratio3.8Cash flow > EarningsY
Price/Sales1085-y EBITDA Growth Rate %-4.0Current Ratio3.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-41.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-49.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M24.1ROIC % (ttm)-119.8Gross Margin Increase y-yN

Gurus Latest Trades with HEB

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

HEB is held by these investors:



HEB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Pascale AdamCFO 2017-02-16Buy6,981$0.4617.39view
Springate Wayne S.Sr VP of Operations 2017-02-16Buy8,014$0.4617.39view
STRAYER DAVID RChief Science/Medical Officer 2017-02-16Buy9,892$0.4617.39view
Springate Wayne S.Sr VP of Operations 2017-02-16Buy8,014$0.4617.39view
Equels Thomas K.CEO, President 2016-12-22Buy68,493$0.73-26.03view
Equels Thomas K.CEO,President 2016-11-01Buy10,000$1-46view
Equels Thomas K.CEO, President 2016-07-08Buy48,000$0.12350view
Equels Thomas K.CEO,President 2016-07-01Buy171,000$0.12350view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-18Buy30,000$0.13315.38view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-11Buy40,000$0.16237.5view

Press Releases about HEB :

Quarterly/Annual Reports about HEB:

News about HEB:

Articles On GuruFocus.com
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 12 2009 
Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

More From Other Websites
Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017 Mar 06 2017
Why President Trump Wants To Transform The FDA – And What It Could Mean For Biotech Stocks Feb 23 2017
$1M deal: Hemispherx plans to sell stock, warrants Feb 03 2017
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Feb 03 2017
Hemispherx Biopharma, Inc. Announces $1 Million Registered Direct Offering Feb 02 2017
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Regulation FD Disclosure Feb 01 2017
Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to... Jan 26 2017
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jan 17 2017
Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to... Jan 11 2017
ETFs with exposure to Hemispherx Biopharma, Inc. : January 3, 2017 Jan 03 2017
HEMISPHERX BIOPHARMA INC Financials Dec 31 2016
ETFs with exposure to Hemispherx Biopharma, Inc. : December 19, 2016 Dec 19 2016
ETFs with exposure to Hemispherx Biopharma, Inc. : December 8, 2016 Dec 08 2016
Crystal Research Associates, LLC Issues Executive Informational Overview on Hemispherx Biopharma,... Dec 01 2016
ETFs with exposure to Hemispherx Biopharma, Inc. : November 23, 2016 Nov 23 2016
Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 Nov 21 2016
Hemispherx 3Q Loss $2.9M or 13 Cents a Share (HEB) Nov 16 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 15 2016
Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended... Nov 14 2016
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15,... Nov 10 2016
Hemispherx Biopharma Featured in Corporate America News Magazine Special Report "Capturing the Power... Nov 08 2016
Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen®... Oct 31 2016
Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone Oct 19 2016
Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case Sep 22 2016
Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards Sep 19 2016
Hemispherx Biopharma, Inc. Announces $5 Million Registered Direct Offering Aug 31 2016
Hemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI's 4th... Aug 29 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 24 2016
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod... Aug 24 2016
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod... Aug 23 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 19 2016
Hemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and... Aug 19 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Aug 17 2016
Hemispherx Biopharma Announces 1-for-12 Reverse Stock Split Aug 17 2016
Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2016 Aug 15 2016
Hemispherx Biopharma Conducts an Interview with The Wall Street Transcript Aug 15 2016
Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production... Jul 27 2016
Hemispherx Announces First Shipment of Rintatolimod (Ampligen®) to Early Access Program in Europe Jul 25 2016
Hemispherx Outlines Key Elements of Strategic Growth Plan and Commitment to Transparency Jul 14 2016
Hemispherx Updates the Status of the Alferon® Manufacturing Facility Jul 11 2016
Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in... Jun 07 2016
Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property Jun 06 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)